Highly Reactive Rubella Spike Ectodomain (E1-E2) Antigen Launched

Laboratory products

Highly Reactive Rubella Spike Ectodomain (E1-E2) Antigen Launched

08 Feb, 2021

Published over 5 years ago. See the latest and most current information on Laboratory products.

Aalto Bio Reagents is pleased to announce the availability of the first highly reactive recombinant Rubella Spike Ectodomain (E1-E2) antigen, code BM 6428, which has shown exceptional detection of both IgG and IgM antibodies in ELISA and bead-based immunoassays. Purified from recombinant expression in insect cells, this high-quality antigen has guaranteed lot to lot consistency and considerably shorter lead times for large lots compared to native antigen production. Using the protein sequence from the Rubella vaccine strain HPV-77, Aalto Bio Reagents was able to produce a very reliable product, ready for use in the development of highly specific IgG and IgM assays.

Transmitted by droplets, Rubella continues to be a widespread infection, particularly in areas where vaccination rates are low. Although the disease typically presents as a mild rash in children, if contracted during pregnancy, the virus can lead to serious foetal abnormalities. Accurate detection of acute Rubella infection is therefore vital. However, reliable detection of IgM antibodies has proved challenging due to the non-specific interferences with other pathogens. It is believed this cross-reactivity is primarily linked to one of the three viral structural proteins – the capsid protein (C). By removing this protein and leaving the two major immunological targets, spike glycoproteins E1 and E2, this new antigen eliminates these potential IgM cross-reactivity issues, leading to less false positives.

CEO of Aalto Bio Reagents, Philip Noone, commented on how the new recombinant Rubella Spike Ectodomain (E1-E2) antigen is a strong contender for the replacement of native Rubella antigens in IVD assays: “There is a very high correlation for IgG and IgM antibody detection with our recombinant antigen versus a commercial native antigen, with our antigen showing 100% sensitivity and between 94.6% to 100% specificity in both ELISA and bead-based assays. Our capsid free antigen overcomes cross-reactivity difficulties and can clearly distinguish between positive and negative samples.”

More information online

Latest News

ILM 51.5 July 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
WATCH: What is the most important aspect of CEMS monitoring?
Explore more Arrow
Pollution Solutions Online
AtkinsRéalis appoints Ian Dyck as global water market lead to drive growth in water infrastructure sector
Explore more Arrow
Petro Online
Reliable jet fuel testing for today’s aviation challenges
Explore more Arrow
Chromatography Today
Affordable liquid chromatography solvent delivery pump
Explore more Arrow